HYDERABAD: Pharma major Aurobindo Pharma is acquiring the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd on a going concern, slump sale basis for a cash consideration of Rs 325 crore in a move aimed at strengthening its presence in the domestic formulations market.The acquisition, done through its wholly owned subsidiary Auro Pharma Limited, takes effect from January 1, 2026, with the cash consideration subject to customary working-capital adjustments, Aurobindo Pharma said in a regulatory filing.The Hyderabad-based company said the acquisition will help it beef up its presence in pain management and anti-infective segments in the Indian market.The acquired business, which comprises 23 established brands across 67 stock-keeping units (SKUs), along with nine pipeline products in these two segments, clocked a turnover of ₹113.5 crore.Though the acquisition will not include limitation inventory, intellectual property, employees, contracts, the acquired business is supported by a field force of approximately 470 personnel and a distribution network of over 1,600 stockists across India, which will give Aurobindo immediate scale and market access in these segments, it added.According to the company, the transaction does not constitute a related-party transaction, and no regulatory or governmental approvals were required.Khandelwal Labs’ acquired business has been operating in the Indian pharmaceutical market since the 1973-74 with stable revenues over the past three years, indicating its maturity and brand recall in prescription markets.